Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 38 of 6351
-
Veterans helping veterans: new study aims to stop suicide
Prevention Recruiting nowThis study examines a novel way to prevent suicide among Veterans with serious mental illness (SMI). It will assess the efficacy of PREVAIL-VA, a 3-month intervention of 12, one-on-one sessions between a Peer Specialist (PS) and a Veteran that involve semi-structured conversation…
Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New CAR-T therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingFRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Light-Activated therapy targets pancreatic tumors during surgery
Disease control Not yet recruitingThis is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
Phase 1/2 • Sponsor: Brown University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingPancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates. Many PDACs arise from non-invasive precursor lesions that develop over years, including pancreatic in…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
A made-to-order DNA vaccine takes aim at liver cancer's return
Vaccine Recruiting nowThis is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to underg…
Phase 2 • Sponsor: Geneos Therapeutics • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC
-
When is the best time to fix other blocked arteries after a heart attack?
Disease control Not yet recruitingThis prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet …
Sponsor: Chonnam National University Hospital • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a targeted antibody stop severe hepatitis from destroying Children's livers?
Disease control Not yet recruitingThe goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who have indeterminate severe hepatitis with T-cell activation and have not responded well to steroids or still need them. This…
Phase 2 • Sponsor: Children's Healthcare of Atlanta • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
Disease control Not yet recruitingHigh pathological complete response (pCR) rates are seen using different neoadjuvant chemotherapy schedules with trastuzumab and pertuzumab in HER2-positive stage II-III breast cancer patients. Total pCR rates in breast and axilla have been described as high as 64%, and with an e…
Phase 3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
Disease control Not yet recruitingThis study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow metastatic breast cancer.
Phase 2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a tiny balloon in the womb help babies breathe?
Disease control Not yet recruitingThe purpose of this pilot study is to evaluate the feasibility of using Fetoscopic Endoluminal Tracheal Occlusion (FETO) in 10 pregnant individuals carrying fetuses with severe congenital diaphragmatic hernia (CDH). FETO surgery will be performed at 27 weeks - 29 weeks and 6 days…
Sponsor: NYU Langone Health • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a triple therapy outsmart Hard-to-Treat esophageal cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma. Participants will receive two cycles of retlirafusp alfa and ch…
Sponsor: RenJi Hospital • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Blood test may reveal stomach cancer before symptoms
Diagnosis Not yet recruitingThe goal of this clinical trial is to prospectively validate the diagnostic performance of an rbcDNA-based assay for gastric cancer detection in individuals undergoing upper gastrointestinal endoscopy. The study aims to evaluate the diagnostic accuracy of rbcDNA in distinguishing…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug combo keep advanced nasopharyngeal cancer at bay?
Disease control Not yet recruitingThis trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1 monoclonal antibody with or without BL-B01D1, as firs…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can new drugs clear Alzheimer's brain plaques?
Disease control Not yet recruitingThe purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzh…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Drones may rush donor lungs to transplant patients, saving precious time
Disease control Not yet recruitingThis prospective, single-arm study will evaluate the feasibility, timeliness, operational reliability, and preliminary safety of transporting donor lungs by a long-range unmanned aircraft system from Nanning to Guangzhou, China. Adult lung transplant candidates will be enrolled a…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can stem cells help infants with biliary atresia avoid a liver transplant?
Disease control Recruiting nowBiliary atresia is a progressive liver disease in infants where liver transplantation is often the only long-term option once cirrhosis develops. However, organ shortages, high costs, risks of graft rejection, and the need for lifelong immunosuppression make transplantation diffi…
Phase 1 • Sponsor: Dr Cipto Mangunkusumo General Hospital • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Can a new pill push hepatitis b virus to undetectable levels?
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demo…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a pill combo keep uveal melanoma from coming back?
Disease control Recruiting nowThis is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Phase 3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A breath sniff could one day screen for lung cancer and more
Diagnosis Not yet recruitingThis prospective multicenter observational study will evaluate whether an electronic nose that analyzes patterns in exhaled breath can be developed as a noninvasive tool for early risk prescreening across several disease areas. The study will enroll up to 20,000 adults from hospi…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a bladder rinse before surgery keep bladder cancer at bay?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H. The main questions it aims to answer are: * Does giving drug Alpha1H before…
Phase 3 • Sponsor: Hamlet Pharma AB • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC